BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 23791799)

  • 1. Early-onset plasmapheresis and LDL-apheresis provide better disease control for pediatric homozygous familial hypercholesterolemia than HMG-CoA reductase inhibitors and ameliorate atherosclerosis.
    Dann EJ; Shamir R; Mashiach T; Shaoul R; Badian A; Stravets T; Kerzman Y; Finkelbaum S; Gaitini D; Lorber A; Bonstein L
    Transfus Apher Sci; 2013 Oct; 49(2):268-77. PubMed ID: 23791799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining the role of lipoprotein apheresis in the management of familial hypercholesterolemia.
    Lee WP; Datta BN; Ong BB; Rees A; Halcox J
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):363-70. PubMed ID: 22149315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low density lipoprotein apheresis in pediatric patients with homozygous familial hypercholesterolemia.
    Coker M; Ucar SK; Simsek DG; Darcan S; Bak M; Can S
    Ther Apher Dial; 2009 Apr; 13(2):121-8. PubMed ID: 19379151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three different schedules of low-density lipoprotein apheresis compared with plasmapheresis in patients with homozygous familial hypercholesterolemia.
    Berger GM; Firth JC; Jacobs P; Wood L; Marais AD; Horak A
    Am J Med; 1990 Feb; 88(2):94-100. PubMed ID: 2105647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-density lipoprotein apheresis as long-term treatment for children with homozygous familial hypercholesterolemia.
    Zwiener RJ; Uauy R; Petruska ML; Huet BA
    J Pediatr; 1995 May; 126(5 Pt 1):728-35. PubMed ID: 7751996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LDL-apheresis: clinical experience and indications in the treatment of severe hypercholesterolemia.
    Thiery J; Seidel D
    Transfus Sci; 1993 Jul; 14(3):249-59. PubMed ID: 10146336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cholesterol efflux mediators in homozygous familial hypercholesterolemia patients on low-density lipoprotein apheresis.
    Nenseter MS; Narverud I; Græsdal A; Bogsrud MP; Aukrust P; Retterstøl K; Ose L; Halvorsen B; Holven KB
    J Clin Lipidol; 2013; 7(2):109-16. PubMed ID: 23415429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apheresis technology for prevention and regression of atherosclerosis.
    Yamamoto A; Harada-Shiba M; Kawaguchi A; Tsushima M
    Ther Apher; 2001 Aug; 5(4):221-5. PubMed ID: 11724504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of homozygous familial hypercholesterolemia with LDL-apheresis on a 4-year-old child].
    Lefort B; Giraud C; Saulnier JP; Bott L; Gambert C; Sosner P; Hankard R
    Arch Pediatr; 2009 Dec; 16(12):1554-8. PubMed ID: 19766469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of LDL-apheresis--more than reduction of cholesterol?].
    Schettler V; Wieland E
    Dtsch Med Wochenschr; 2007 Mar; 132(11):575-8. PubMed ID: 17342636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From plasma-exchange to LDL-apheresis: new developments in the treatment of familial hypercholesterolemia.
    Postiglione A; Gnasso A; Mastranzo P; Montefusco S; Motti C; Gallotta G; Cortese C; Scarpato N
    Beitr Infusionsther; 1988; 23():74-80. PubMed ID: 2484784
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term effects of LDL apheresis in patients with severe hypercholesterolemia.
    Sachais BS; Katz J; Ross J; Rader DJ
    J Clin Apher; 2005 Dec; 20(4):252-5. PubMed ID: 15880364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of LDL apheresis on aortic root atheroma in children with homozygous familial hypercholesterolemia.
    Lefort B; Saheb S; Bruckert E; Giraud C; Hequet O; Hankard R
    Atherosclerosis; 2015 Mar; 239(1):158-62. PubMed ID: 25608117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute and long-term effects of low-density lipoprotein (LDL)-apheresis on oxidative damage to LDL and reducing capacity of erythrocytes in patients with severe familial hypercholesterolaemia.
    Stefanutti C; Di Giacomo S; Vivenzio A; Isacchi GC; Masella R; Caprari P; Varì R; Tarzia A; Mosiello A; Cantafora A
    Clin Sci (Lond); 2001 Feb; 100(2):191-8. PubMed ID: 11171288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homozygous familial hypercholesterolemia: long term clinical course and plasma exchange therapy for two individual patients and review of the literature.
    Beigel R; Beigel Y
    J Clin Apher; 2009; 24(6):219-24. PubMed ID: 19902516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia.
    Richter WO; Donner MG; Höfling B; Schwandt P
    Metabolism; 1998 Jul; 47(7):863-8. PubMed ID: 9667236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coronary atherosclerosis reduced in patients with familial hypercholesterolemia after intensive cholesterol lowering with low-density lipoprotein-apheresis: 1-year follow-up study. The Osaka LDL-Apheresis Multicenter Trial Group.
    Kitabatake A; Sato H; Hori M; Kamada T; Kubori S; Hoki N; Minamino T; Yamada M; Kato T
    Clin Ther; 1994; 16(3):416-28. PubMed ID: 7923308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Lipoprotein(a) is associated to atherosclerosis in primary hypercholesterolemia].
    Bea AM; Mateo-Gallego R; Jarauta E; Villa-Pobo R; Calmarza P; Lamiquiz-Moneo I; Cenarro A; Civeira F
    Clin Investig Arterioscler; 2014; 26(4):176-83. PubMed ID: 24576773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-Term Follow-Up of a Homozygous Familial Hypercholesterolemic Patient Receiving Regular Double Filtration Plasmapheresis - Case Report and Literature Review.
    Tsai JL; Wu MJ; Shu KH; Tsai SF
    Blood Purif; 2016; 41(4):264-9. PubMed ID: 26731699
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of severe familial heterozygous hypercholesterolemia by low-density lipoprotein apheresis with immunoadsorption: effects of the addition of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to therapy.
    Jacob BG; Richter WO; Schwandt P
    Clin Investig; 1993 Nov; 71(11):908-12. PubMed ID: 8312683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.